Latest Headlines

  1. AST Celebrates 60 Years Of Excellence In Innovation And Looks To The Future Of Drug Product Manufacturing 5/1/2025

    AST marked the launch of its 60th anniversary year at INTERPHEX 2025, using the prestigious industry event as a springboard to highlight six decades of innovation. Building on the momentum of being named “Best in Show” at INTERPHEX 2024, AST entered its 60th anniversary receiving another reputable honor: the INTERPHEX Efficiency Champion award. This back-to-back recognition highlights not only AST’s legacy of innovation but also its forward-looking approach to advancing excellence across the industry.

  2. RoosterBio Announces Collaboration With Thermo Fisher Scientific To Advance Cell And Exosome Therapy Manufacturing 4/29/2025

    RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science.

  3. Cytiva And Asimov Collaborate On Next Generation Cell Line Design And Process Development 4/29/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva, a global life sciences leader, to provide customers with an integrated offering for optimized biologics production.

  4. Avance Clinical To Showcase Asia-Pacific Clinical Trial Expertise At BIO Korea 2025 4/15/2025

    Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech research services, will attend BIO Korea 2025 to meet with biotechs and share clinical trial capabilities across the region including Australia, New Zealand, South Korea, Taiwan, North America and beyond.

  5. Nikon CeLL Innovation Enters Into A Strategic License Agreement With RoosterBio 4/15/2025

    Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBio), a leading stem cell technology company in the US.

  6. Novotech Expands South Korean Presence With New Hospital Trial Site Deal 4/4/2025

    Australian CRO Novotech has signed a memorandum of understanding with the Kyungpook National University Hospital (KNUH), furthering its partnership strategy in South Korea.

  7. Novotech Named Best Contract Research Organization In Australia At Asia-Pacific Biopharma Excellence Awards 2025 4/3/2025

    Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market has been recognized as the Best Contract Research Organization in Australia at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2025. 

  8. Novotech Report Reveals Growth In siRNA Research 4/3/2025

    Sydney, March 2025 – Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of small interfering RNA (siRNA) therapeutics. This report provides insights for biotech and pharmaceutical companies leveraging RNA-based precision medicine to develop next-generation treatments for oncology, metabolic disorders, and rare genetic diseases. 

  9. Landmark Bio Acquired By Artis BioSolutions To Expand Manufacturing And Commercialization Of Advanced Therapies 4/2/2025
  10. Miltenyi Biotec To Commercially Supply CliniMACS® Platform To Autolus Therapeutics For Its Manufacture Of FDA-Approved AUCATZYL® (Obecabtagene Autoleucel – Obe-Cel) 3/28/2025

    Miltenyi Biotec, a global leader innovating technologies and services for patient-specific cell and gene therapies, today announced that it will supply Miltenyi Biotec’s CliniMACS Prodigy® instruments, reagents, and disposables for the manufacture of Autolus’ FDA-approved AUCATZYL® (obecabtagene autoleucel), as part of its longstanding partnership with the CAR T cell therapy developer since 2018.